Medindia

X

/C O R R E C T I O N -- BioElectronics Corporation/

Friday, May 16, 2008 General News J E 4
Advertisement
In the news release, BioElectronics (Pink Sheets: BIEL) AnnouncesConference Call to Update Investors on Growth Initiatives, we are advised bythe company that the third paragraph, first sentence, should read "Theconference call will be held on Tuesday, May 20, 2008 at 4:15 p.m. (EDT)"rather than "March 20, 2008" as originally issued inadvertently.



------

BioElectronics Announces Conference Call to Update Investors on Growth Initiatives

CEO Andrew Whelan to present Corporate Growth Plan on Tuesday, May 20th

FREDERICK, Md., May 15 /PRNewswire-FirstCall/ -- BioElectronics Corp.(Pink Sheets: BIEL), the maker of the ActiPatch(TM), a drug freeanti-inflammatory patch with an embedded battery operated microchip deliveringweeks of continuous pulse therapy for a few cents an hour, today announced itwill hold a conference call to update investors on the growth initiativesimplemented by the company. Andrew Whelan, President and CEO of BioElectronicsCorp. will outline the important changes made in 2007 to realign the companyfor growth and the successes currently being realized both domestically andinternationally.

"These are very exciting times for BioElectronics Corporation. During2007 we made many changes to the organization to realign in preparation forsignificant revenue growth," commented Mr. Whelan. "These changes are startingto yield dividends in the form of the introduction of many new products, agrowing distributor base, and most importantly, strong revenue growth. Pleasejoin us next week as we outline the changes we have made to the organizationand our exciting growth prospects for 2008 and beyond."

The conference call will be held on Tuesday, March 20, 2008 at 4:15 p.m.(EDT). To access the conference call from within the United States and Canadaplease dial (800) 610-4500 and enter access code 37321. To access the callfrom locations outside of the United States and Canada, please dial(702) 851-3339 and enter access code 37321.

About BioElectronics Corporation

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatchis a drug-free anti-inflammatory patch with an embedded battery operatedmicrochip that delivers weeks of continuous pulsed therapy for about a dollara day. The unique ActiPatch delivery system, using patented technology,provides a cost-effective patient friendly method to reduce soft tissue painand swelling. ActiPatch is approved by Health Canada for the relief of painin musculoskeletal complaints. The US government's Food and DrugAdministration (FDA) has cleared the use of the product for reducing edema(swelling) following blepharoplasty and the European Union has approved theproduct as a class II pulsed electromagnetic medical device as have numerousother international regulatory agencies. Information on ActiPatch andBioElectronics Corporation is available at the following websites:

Safe Harbor Statement

This news release contains forward-looking statements related to futuregrowth and earnings opportunities. Such statements are based upon certainassumptions and assessments made by management in light of current conditions,expected future developments and other factors it believes to be appropriate.Actual results may differ as a result of factors over which the company has nocontrol.-- U.S. Consumer http://www.actipatchonline.com -- Podiatry: http://www.pemfpodiatry.com -- Plastic Surgery: http://www.plasticsurgeryrelief.com and http://www.makemeheal.com -- German orthopedic foot & ankle: http://www.diesfussexperten.de -- Italy and Switzerland: http://www.actipatch.it -- Canada: http://www.actipatchpaintherapy.ca -- Netherlands: http://www.actipatch.de -- Singapore & Malaysia: http://www.astonixlife.com/ -- BioElectronics Corp: http://www.bioelectronicscorp.com

SOURCE BioElectronics Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Landmark ATHENA Study Findings With Multaq(R) (dro...
S
Depth of MedImmune's Respiratory Disease Research ...